Search
Close this search box.

Elias Zerhouni to chair Boston Pharmaceuticals

ARTICLE | Management Tracks

Plus: SystImmune names Jonathan Cheng CMO, and updates from CRISPR, SynaptixBio, Enable Injections and Anavex

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst

May 23, 2024 11:07 PM UTC

Liver disease company Boston Pharmaceuticals Inc. named Elias Zerhouni chair, succeeding Stefan Meister, who is stepping down to focus on his roles outside the company. Zerhouni was director of the National Institutes of Health from 2002 to 2008, and was most recently president of global R&D at Sanofi (Euronext:SAN; NASDAQ:SNY). 

SystImmune Inc. hired Jonathan Cheng to succeed CMO Martin Olivo, who is leaving to pursue other opportunities. Cheng was SVP and therapeutic area oncology head at Bristol Myers Squibb Co. (NYSE:BMY)…